Can the Monocyte/HDL Ratio be used as A Marker to Predict Fatty Liver and Its Stages?
Monocyte/HDL Ratio and Fatty Liver
Abstract views: 195
/ 
PDF downloads: 106
DOI:
https://doi.org/10.5281/zenodo.8134906Keywords:
hepatosteatosis, inflammation, insulin resistance, monocyte/HDL ratio, non-alcoholic fatty liver diseaseAbstract
Background: Our study aims to determine whether the monocyte/HDL ratio is a marker that can be used to predict the presence and stage of non-alcoholic fatty liver.
Material and Method: Patients aged 18-65 years without known chronic diseases and medication use who applied to our hospital for a check-up were included in the study. Patients were divided into 4 groups based on ultrasonography findings: those without hepatosteatosis, those with stage 1, stage 2, and stage 3 hepatosteatosis. Groups were compared in terms of fasting glucose, insulin resistance, lipid profile, liver function tests, monocyte/HDL ratios.
Results: Fasting glucose, insulin resistance, total cholesterol, LDL cholesterol, triglycerides, alanine aminotransferase, monocytes, and monocyte/HDL ratio were significantly higher in the group with hepatosteatosis than in the group without hepatosteatosis, and this increase was directly proportional to the stage. HDL was significantly lower in the hepatosteatosis group than in the group without hepatosteatosis, and HDL decreased further as the stage of hepatosteatosis increased. No difference was found between the groups in terms of aspartate aminotransferase. Multivariate regression analyses revealed that hepatosteatosis was independently associated with alanine aminotransferase, insulin resistance, and monocyte/HDL ratio.
Conclusion: Monocyte/HDL ratio can be considered a simple, easily accessible, and inexpensive marker to predict the presence and stages of hepatosteatosis.
References
Gören B, Fen T. Non-Alkolik Yağlı Karaciğer Hastalığı. Turkiye Klinikleri J Med Sci. 2005;25(6):841-50.
Kim GA, Lee HC, Choe J, et al. Association between non-alcoholic fatty liver disease and cancer incidence rate [published online ahead of print, 2017 Nov 2]. J Hepatol. 2017;S0168-8278(17)32294-8. doi:10.1016/j.jhep.2017.09.012
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi:10.1002/hep.28431
Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223-238. doi:10.1038/s41575-020-00381-6
Sonsuz A. Nonalkolik karaciğer yağlanması. İÜ Cerrahpaşa Tıp Fakültesi Sürekli Tıp Eğitimi Etkinlikleri. 2007;58:91-98.
Long MT, Gandhi S, Loomba R. Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease. Metabolism. 2020;111S:154259. doi:10.1016/j.metabol.2020.154259
Ajmera V, Perito ER, Bass NM, et al. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology. 2017;65(1):65-77. doi:10.1002/hep.28776
Wong VW, Adams LA, de Lédinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15(8):461-478. doi:10.1038/s41575-018-0014-9
Huang H, Wang Q, Shi X, et al. Association between Monocyte to High-Density Lipoprotein Cholesterol Ratio and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study. Mediators Inflamm. 2021;2021:6642246. Published 2021 Dec 7. doi:10.1155/2021/6642246
Yozgat A, Ekmen N, Kasapoglu B, Unsal Y, Sokmen FC, KEKiLLi M. MONOCYTE/HDL RATIO IN NON-ALCOHOLIC HEPATIC STEATOSIS. Arq Gastroenterol. 2021;58(4):439-442. doi:10.1590/S0004-2803.202100000-80
Säemann MD, Poglitsch M, Kopecky C, Haidinger M, Hörl WH, Weichhart T. The versatility of HDL: a crucial anti-inflammatory regulator. Eur J Clin Invest. 2010;40(12):1131-1143. doi:10.1111/j.1365-2362.2010.02361.x
Pirmoazen AM, Khurana A, El Kaffas A, Kamaya A. Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease. Theranostics. 2020;10(9):4277-4289. Published 2020 Mar 4. doi:10.7150/thno.40249
Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745-750. doi:10.1053/gast.2002.35354
Hilgendorf I, Swirski FK, Robbins CS. Monocyte fate in atherosclerosis. Arterioscler Thromb Vasc Biol. 2015;35(2):272-279. doi:10.1161/ATVBAHA.114.303565
Murphy AJ, Woollard KJ. High-density lipoprotein: a potent inhibitor of inflammation. Clin Exp Pharmacol Physiol. 2010;37(7):710-718. doi:10.1111/j.1440-1681.2009.05338.x
Köylü E, Kurtoğlu YK. Relationship between elevated monocyte-HDL ratio, an inflammatory marker, with smoking. The Journal of Turkish Family Physician. 2021;12(1):22-31.
Ersoy İ, Ersoy P. Yeni kardiyovasküler risk belirteçleri plazma aterojenik indeksi, nötrofil/lenfosit oranı ve monosit HDL oranı obezitede nasıl etkilenmektedir? Kesitsel retrospektif bir çalışma. Kocatepe Tıp Dergisi. 2022; 23(1):1-6.
Tessari P, Coracina A, Cosma A, Tiengo A. Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2009;19(4):291-302. doi:10.1016/j.numecd.2008.12.015
Allen AM, Van Houten HK, Sangaralingham LR, Talwalkar JA, McCoy RG. Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large U.S. Claims Database. Hepatology. 2018;68(6):2230-2238. doi:10.1002/hep.30094
Karaaslan Ö, Ekizler FA, Özilhan MO, Çoteli C, Ünal S, Maden O. Akut Miyokardit Hastalarında Monosit/HDL Kolestrol Oranı ile Klinik Sonlanımlar Arasındaki İlişki. Ankara Üniversitesi Tıp Fakültesi Mecmuası. 2021;74(1):76-82.
Aydin E, Ates I, Fettah Arikan M, Yilmaz N, Dede F. The ratio of monocyte frequency to HDL cholesterol level as a predictor of asymptomatic organ damage in patients with primary hypertension. Hypertens Res. 2017;40(8):758-764. doi:10.1038/hr.2017.36
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. doi:10.1002/hep.29367
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes Facts. 2016;9(2):65-90. doi:10.1159/000443344
Sheth SG, Chopra S. Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults. UpToDate. Waltham, MA. 2017.
Fon Tacer K, Rozman D. Nonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation. J Lipids. 2011;2011:783976. doi:10.1155/2011/783976
Fan N, Peng L, Xia Z, et al. Triglycerides to high-density lipoprotein cholesterol ratio as a surrogate for nonalcoholic fatty liver disease: a cross-sectional study. Lipids Health Dis. 2019;18(1):39. Published 2019 Feb 2. doi:10.1186/s12944-019-0986-7
Milić S, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis. 2012;30(2):158-162. doi:10.1159/000336669
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Ece Yiğit, İlknur Sayar
This work is licensed under a Creative Commons Attribution 4.0 International License.
The journal is licensed under a 